Introduction
Axonal transport is a simultaneous flow of proteins and organelle cargoes, essential for neurons to sustain their viability and maintain their function 1, 2 . Classically, two types of axonal transport have been distinguished-anterograde transport, from the neuronal cell body to the nerve terminal, and retrograde transport, from the terminal to the neuronal body 3 , (Figure 1 ). Defective axonal transport has been linked to a number of diseases, i.e.: a) adultonset neurodegenerative diseases, AONDs 4, 5 , a set of dysfunctional and degenerative disorders affecting different populations of neurons; b) motor neuron disorders such as: amyotrophic lateral sclerosis 6, 7 , distal hereditary motor neuropathy 8 , spinal muscular atrophy 7 , hereditary spastic paraplegia 9 ; c) Alzheimer's, Parkinson's and Huntington's and related disorders [10] [11] [12] [13] ; and d) Charcot-Marie-Tooth disease (CMT), a heterogeneous group of hereditary motor and sensory neuropathies 1, 14 . Recently, disturbances in axonal transport have also been shown in neurological complications of diabetes [15] [16] [17] [18] [19] . Molecular mechanisms underlying axonal transport deficiencies vary between diseases and might be divided into four categories related to dysfunction of: 1) molecular motors (kinesin and dynein) 2) microtubules, 3) cargoes and 4) mitochondria. During the last two decades, tremendous progress has been made in studies on axonal transport deficiencies, mainly related to molecular motor and microtubule mutations; however, there are still many open questions. It remains unclear what the regulatory mechanisms of axonal transport are, what the role of posttranslational processes in motor-cargo binding is and finally, what role is played by impairment of the cytoskeletal and cytoskeleton regulatory cargo proteins in the development of neurodegenerative disease. Here, in this review, we will focus on the axonal transport of two major cytoskeletal proteins, that is, neurofilament and actin and two interrelated cytoskeletal regulatorsmammalian Diaphanous 1 (mDia1) and Liprin α in neurodegenerative disorders. Neurofilament and actin transported as cargo by microtubules are major elements of the neuronal cytoskeleton framework 20, 21 and play a role in neuronal morphogenesis and neuron-glial interactions, while mDia1 and Liprin α act in tandem as cytoskeletal regulators playing a role in stress fibre remodelling and cytoskeletal formation ( Table 1, Figure 2 ).
Discussion
The author has referenced some of its own studies in this review. The protocols of these studies have been approved by the relevant ethics committees related to the institution observed that mutations in the kinesin 1 subunit-KIF5A in hereditary spastic paraplegia affects neurofilament transport leading to its accumulation and likely contribution to the development of the disease 39 . Further, studies in mice with the inactive KIF5A gene revealed that such inactivation leads to neurofilament accumulation and changes in axon morphology often resulting in neuronal degeneration and paralysis 40 . Similarly, functional blockade of dynein resulted in neurofilament transport impairment and alternations of axonal structure 41 . Another study, investigating the role of dynactin-dynein activator complex in the p150
Glued mouse model showed an excess of neurofilament in spinal cord axons that likely contributes to motor neuron disease pathogenesis 42 . Studies on neurofilament structure and function revealed that singular deletions of neurofilament subunits led to neurofilament axonal transport impairment, reduction in axonal calibre and neuronal number reduction 14, [43] [44] [45] . In particular, it has been shown that light chain mutation is instrumental in the development of Charcot-MarieTooth disease and leads to defective axonal transport and impaired assembly of neurofilament
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. Pathological, post-translational changes of neurofilament structure, such as extensive phosphorylation [46] [47] [48] and nonenzymatic glycation 46, 49, 50 have also been shown to affect neurofilament transport, resulting in neurofilament accumulation and consequently altering axonal structure and function leading to nerve degeneration. Recent experiments focused on axonal transport impairment in the diabetic peripheral nerve revealed that neurofilament transport is indeed delayed and this delay coincides with the increased level of Carboxymethyllysine (CML), an advanced glycation end-product (AGE) indicative of high levels of glycation likely affecting neurofilament structure 19 . in which they were performed. Animal care was in accordance with the institution guidelines.
Neurofilaments
Neurofilaments belong to the family of intermediate filaments and are the most abundant cytoskeletal elements in the mammalian nervous system 22, 23 , playing a role in axonal calibre regulation, neuronal differentiation and axonal outgrowth and regeneration 23 . In healthy nerve tissue, neurofilaments are transported by members of two different protein families: microtubule-kinesin and dynein 24, 25 , and microfilament-myosin 26, 27 at a slow rate, in an intermittent, stop and go, manner 28, 29 . Time-lapse experiments revealed that the average rate of neurofilament transport is that of fast axonal transport but it is delayed by continuous pauses for prolonged periods of time 30 ; this breakthrough observation laid ground for the current view of neurofilament transportation in the nervous system and provided insight into general mechanisms governing cytoskeletal protein cargo transportation. Even before that discovery, irrespective of the nature of neurofilament axonal transport, many authors noted that its impairment may contribute to the pathogenesis of neurodegenerative diseases such as: ALS [31] [32] [33] [34] , Charcot-Marie-Tooth 19, 38 . Impairment of neurofilament axonal transport might be caused by mutations/ change of function of transport proteins (indirect cause) or by changes in the neurofilament structure and/ or function (direct cause). It has been Similarly, in other neurodegenerative disorders such as Parkinson's, Alzheimer's or Amyotrophic lateral sclerosis, it has been shown that extensive phosphorylation of neurofilament often correlated with increased glycation, affecting neurofilament transport and leading to abnormal neuronal aggregation of neurofilaments, resulting in neurodegenerative changes [51] [52] [53] [54] .
Actin
Actin, another abundant cytoskeletal protein, belonging to the microfilament family, is involved in numerous cellular functions, maintaining interaction between various cytoskeletal elements. In the nervous system, actin plays a role in the growth cone and axonal guidance, and regulates transport of microtubules. It has been shown that in dopaminergic neurons, actin-neurofilament interaction plays a role in maintaining neuronal structure and function 55 . Additionally, it has been reported that neurofilament transport depends partially on actin and actin-binding myosin, indicating that actin might be a limiting factor in maintaining proper transport and distribution of neurofilament 26 . Similarly, actin is transported at a slow rate to the neurofilament by molecular motors, constituting, along with other proteins, slow component b. Recent studies have revealed that impairment of actin axonal transport has been reported in a number of neurodegenerative diseases such as spinal muscle atrophy 56 , Alzheimer's 57,58 , Parkinson's-related α-synucleinopathy 59 or diabetic neuropathy 15 . Mechanisms underlying the impairment of actin axonal transport are not clearly established but, as in the case of neurofilament, it is speculated that structural and/ or functional changes in molecular motor and cytoskeleton-associated proteins are causative of the observed impairment. It has been observed, for example, in studies on It has been shown that transport of both actin and neurofilament is impaired in neurodegenerative disease, either as a result of their genetic mutations or post-translational changes such as glycation and excessive phosphorylation that alter their structure. Structural changes alter their binding properties and affect protein interactions triggering a cascade of abnormal pathological events leading to neurodegeneration and the development of neurodegenerative diseases. mDia1 and Liprin α, interrelated proteins and binding partners interact with molecular motors, affecting transport of cytoskeleton proteins. It might be speculated that in pathological conditions, their transport is correlated with pathological changes affecting cytoskeletal proteins such as neurofilament and actin, further aggravating axonal transport impairment and contributing to neurodegenerative disorder pathogenesis.
neuropathic nerve revealed that mDia1 axonal transport is impaired in diabetes independently of mouse genotype
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. The study, utilizing stop flow, crush technique, showed that mDia1 accumulation at the crushed side of the peripheral nerve was decreased 3 and 6 hours after the crush, which is indicative of impaired axonal transport and suggests a link between diabetic neurological changes and axonal transport alternation. Lower levels of mDia1 correlated with increased CML and RAGE levels indicating that observed changes might be a result of glycation-evoked actin structural alternations affecting proper mDia1-actin binding and disabling its transport.
Liprin α
Liprin α, a member of the LAR protein-tyrosine phosphatase-interacting protein family, is a cytoskeletal protein binding partner recently discovered to interact with mDia1 67 , and through this interaction regulate actin stress fibre formation in the cell. It has been shown that Liprin α deficiencies, as observed in Syd2-and Dliprin-knock out animals, revealed that it is essential for synaptic active zone formation, axonal growth and neurotransmission.
Liprin α axonal transport has not been yet fully investigated; however, reports studying its role in active zone formation 68 and axonal transport regulation 69 revealed that Liprin α is probably transported in an unpacked form 68 and is actively involved in the transport itself 16 . The latter study, investigating Liprin α interaction with Kinesin-3 UNC-104 (KIF1A) showed that Liprin α serves as an adaptor of molecular motor, such as KIF1A, activity, regulating its motility 16 . No study has yet focused on Liprin α axonal transport in neurodegenerative disorders; however, from the amount of evidence showing its diverse role in synapse activity and its involvement via mDia1 and KIF1A interactions in axonal Huntington's disease-related axonal transport disturbances, that Rab3 and Huntington complex was involved in actin transport and its disruption led to alternations in actin axonal transport 60 . Another study, conducted in Alzheimer's model PS1/APP mice, revealed that the presence of phosphorylated tau protein affects molecular motors and the actin cytoskeleton, likely leading to alternations of axonal transport and abnormal metabolism of these proteins 58 . Observed impairment in actin axonal transport might be also contributed, as in case of neurofilament, to increased levels of glycation leading to subsequent changes in actin chemical structure that affect axonal transport 19, 61 .
mDia1
Mammalian Diaphanous 1, mDia1, belongs to the family of actin polymerizing formins and is involved in a number of microtubule and microfilament-related remodelling processes 62 . In the nervous system, mDia1 is involved in actin stress fibre formation, neuronal migration and morphogenesis during development 63, 64 . It has been shown that mDia1 deficiency leads to severe morphological and physiological changes in the neuroepithelial cell layer of the brain, halting hydrocephalus development and leading to excessive production of periventricular masses 65 . Recent studies have shown that mDia1, along with its cytoskeleton protein interactions, also binds to RAGE 66 , a proinflammatory receptor for advanced glycation end products, activated during increased glycation and oxidative stress. Studies investigating mDia1 axonal transport have been scarce so far; however, there is emerging evidence that its impairment might also be involved in the development of neurodegenerative disorders. The first report, investigating mDia1 distribution in wildtype and RAGE knock out diabetic
